BeiGene nabs accelerated review in China for pamiparib application

China’s National Medical Products Administration has granted priority review status to BeiGene’s (BGNE -0.5%) marketing application seeking approval of dual PARP inhibitor pamiparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more lines of chemotherapy.

Priority review status in China, similar to the U.S., allows for accelerated review and approval timelines.

https://seekingalpha.com/news/3595212-beigene-nabs-accelerated-review-in-china-for-pamiparib-application